CIK 0000882095
- Large accelerated filer
GILEAD SCIENCES, INC.
Sign in to watch- Ticker
- GILD
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 943047598
- Phone
- +1 650-574-3000
- Business address
- 333 LAKESIDE DR, FOSTER CITY, CA, 94404
- Former names
- GILEAD SCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $36,996,096
- in 12 filings, $37.0M under 10b5-1 plans
Net −$36,996,096. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-03-10 | Mercier Johanna Chief Commercial Officer | Option exercise | +3,025 | 79,390 | ||
| 2023-03-10 | Mercier Johanna Chief Commercial Officer | Option exercise | +7,951 | 87,341 | ||
| 2023-03-10 | Mercier Johanna Chief Commercial Officer | Shares withheld for taxes | −5,116 | $79.50 | $407K | 82,225 |
| 2023-03-10 | Mercier Johanna Chief Commercial Officer | Option exercise · Restricted Stock Unit | −3,025 | 47,283 | ||
| 2023-03-10 | Mercier Johanna Chief Commercial Officer | Option exercise · Restricted Stock Unit | −7,951 | 39,332 | ||
| 2023-03-10 | Mercier Johanna Chief Commercial Officer | Grant or award · Restricted Stock Unit | +16,350 | 55,682 | ||
| 2023-03-10 | Mercier Johanna Chief Commercial Officer | Grant or award · Non-qualified Stock Option (Right to Buy) | +74,565 | 74,565 | ||
| 2023-03-10 | Dickinson Andrew D Chief Financial Officer | Option exercise | +3,025 | 108,643 | ||
| 2023-03-10 | Dickinson Andrew D Chief Financial Officer | Option exercise | +7,394 | 116,037 | ||
| 2023-03-10 | Dickinson Andrew D Chief Financial Officer | Shares withheld for taxes | −4,849 | $79.50 | $385K | 111,188 |
| 2023-03-10 | Dickinson Andrew D Chief Financial Officer | Option exercise · Restricted Stock Unit | −3,025 | 39,644 | ||
| 2023-03-10 | Dickinson Andrew D Chief Financial Officer | Option exercise · Restricted Stock Unit | −7,394 | 32,250 | ||
| 2023-03-10 | Dickinson Andrew D Chief Financial Officer | Grant or award · Restricted Stock Unit | +16,350 | 48,600 | ||
| 2023-03-10 | Dickinson Andrew D Chief Financial Officer | Grant or award · Non-qualified Stock Option (Right to Buy) | +74,565 | 74,565 | ||
| 2023-03-10 | Telman Deborah H EVP, Corporate Affairs & GC | Grant or award · Restricted Stock Unit | +10,220 | 43,140 | ||
| 2023-03-10 | Telman Deborah H EVP, Corporate Affairs & GC | Grant or award · Non-qualified Stock Option (Right to Buy) | +46,605 | 46,605 | ||
| 2023-03-09 | Lofton Kevin E Director | Option exercise | +8,442 | $52.38 | $442K | 8,442 |
| 2023-03-09 | Lofton Kevin E Director | Option exercise · Non-qualified Stock Option (Right to Buy) | −8,442 | 0 | ||
| 2023-03-01 | Parsey Merdad Chief Medical Officer | Sale | −12,984 | $79.96 | $1.0M | 70,130 |
| 2023-03-01 | O'Day Daniel Patrick Chairman & CEO | Option exercise | +11,362 | 364,337 |
Page 37 of 43 · 851 trades